One state is fighting its physician shortage by creating a new pathway for experienced IMGs to practice in the US; the AMA has taken steps to ease the path to licensing for other IMGs.
Insurance companies are starting to send warning letters to doctors and health care providers suspected of a practice known as off-label prescribing for the drug Ozempic.